Biotech: Page

  • A sign with Biogen's logo sits outside the company's Cambridge, Massachusetts, headquarters on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Biogen plots new global headquarters in Kendall Square

    The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.

    By • March 24, 2025
  • An illustration of a brain disintegrating
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Tempero Bio gets $70M to advance substance abuse treatment

    The Series B round will help the Aditum Bio-backed startup fund two mid-stage clinical trials in people with alcohol and cocaine use disorders.

    By • March 24, 2025
  • Colorized scanning electron micrograph of a natural killer cell from a human donor. Explore the Trendline➔
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Cell therapy

    The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

    By BioPharma Dive staff
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    AstraZeneca deepens China investment; Editas loses CFO to Dyne

    The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.

    By BioPharma Dive staff • March 21, 2025
  • An Alnylam logo is displayed on a building in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Alnylam prices heart drug at premium to rivals

    Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio. But executives argue its “compelling and highly differentiated value” justify the higher charge.

    By • March 21, 2025
  • An Alnylam logo is displayed on a building in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Alnylam drug gets long-awaited FDA approval in deadly heart disease

    Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a fast-changing market.

    By • Updated March 20, 2025
  • An illustration of engineered CAR-T cells attacking a cancer cell.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Cargo shelves cell therapy research, lays off more staff

    CEO Gina Chapman is also departing the company, which plans to review options for pursuing a reverse merger or other business combination.

    By • March 19, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Stoke CEO exits; Medicare drug price talks advance

    Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers targeted for second round of Medicare price talks agreed to participate.

    By BioPharma Dive staff • March 18, 2025
  • A red magnifying glass sits on top of cash.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Sofinnova’s latest biotech fund sprouts three new startups

    As part of its “pan-European” plans, Sofinnova is backing startups developing treatments for fibrosis, cancer and Alzheimer’s.

    By • March 18, 2025
  • A Sarepta logo is displayed on a building in Cambridge, Massachusetts on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Duchenne patient dies after receiving Sarepta gene therapy

    A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the treatment in the future, some analysts wrote.

    By • Updated March 18, 2025
  • An illustration of DNA against a blue abstract background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Gene editing

    Arbor raises $74M amid genetic medicine’s funding slump

    The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients have with therapies from Alnylam and Novo Nordisk.

    By • March 18, 2025
  • Two cancerous cells flow through a blood vessel in this stylized illustration
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Orca Bio to seek approval of T cell transplant after positive trial data

    Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant in treating certain blood cancers.

    By Ned Pagliarulo • March 17, 2025
  • header image
    Image attribution tooltip
    Permission granted by 1nHealth
    Image attribution tooltip
    Sponsored by 1nHealth

    How biotech and pharma teams are reaching LPI ahead of schedule

    With the right strategy, reaching LPI ahead of schedule isn’t a myth. Learn how some biotech and pharma teams are achieving the impossible.

    By Katie Rodammer and Ryan Day • March 17, 2025
  • A microscopic view of a nerve cell, containing magenta dots on a blue and black wave texture background.
    Image attribution tooltip
    Courtesy of Nwasinachi Adriana Ezeji/Center for Advanced Pain Studies, University of Texas, Dallas
    Image attribution tooltip
    Pain drugs

    Latigo raises $150M to get non-opioid pain drugs through key tests

    The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for its lead candidate.

    By • March 17, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’

    President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell and gene therapy pilot appeared to survive.

    By BioPharma Dive staff • March 14, 2025
  • An illustration of an adeno-associated virus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup

    The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a “transformative” deal, according to the company’s CEO.

    By • March 13, 2025
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip
    Obesity drugs

    Roche broadens obesity drug plans with $1.65B Zealand deal

    The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs it acquired from Carmot.

    By • March 12, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

    Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is departing after 14 years.

    By BioPharma Dive staff • March 12, 2025
  • A group of scientists and executives with Lila Sciences.
    Image attribution tooltip
    Permission granted by Lila Sciences
    Image attribution tooltip

    Flagship startup raises $200M in pursuit of ‘scientific superintelligence’

    Funded by investors such as Flagship and General Catalyst, the AI startup claims its platform will help scientists speed up the experimentation process.

    By • March 12, 2025
  • An illustration of red and white blood cells clustered against a pink background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Ono pays $280M to license Ionis rare disease drug

    Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.

    By Kristin Jensen • March 12, 2025
  • CordenPharma’s Integrated Supply from peptide drug substance to injectable and oral solid dosage manufacturing.
    Image attribution tooltip
    Courtesy of CordenPharma
    Image attribution tooltip

    Viking inks CordenPharma deal to boost obesity drug supply

    The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched weight loss treatment.

    By • March 11, 2025
  • Scientific illustration of a migrating breast cancer cell
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Arvinas gets positive breast cancer data, but finds differentiation a hard sell

    Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a subgroup of breast cancer patients, but not the overall study population.

    By Ned Pagliarulo • March 11, 2025
  • Futuristic 3D cubes showing DNA base pairs and a double helix.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Gene editing

    Beam base editing therapy gets ‘proof of concept’ in rare lung disease

    While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell by double digits.

    By Ned Pagliarulo • March 10, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roche launches new Boston center; NIH centralizes peer review

    The Swiss pharma will base cardiometabolic drug research at the new Allston site. Elsewhere, AskBio, Bayer’s gene therapy subsidiary, advanced an experimental treatment for limb-girdle muscular dystrophy. 

    By BioPharma Dive staff • March 7, 2025
  • Portrait of Jeb Keiper, CEO of Nimbus Therapeutics.
    Image attribution tooltip
    Permission granted by Nimbus Therapeutics
    Image attribution tooltip

    Nimbus swaps CEOs and turns to new leader for ‘next chapter’

    CBO Abbas Kazimi will replace longtime CEO Jeb Keiper as part of a planned leadership transition at the unorthodox drug startup.

    By • March 7, 2025
  • A bottle of Vertex Pharmaceuticals' new pain medicine Journavx.
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip
    Pain drugs

    Vertex’s new pain drug gets first coverage nod from major insurer

    Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in an interim decision while a formal review continues.

    By • March 6, 2025